SPDR S&P Biotech ETF
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
23.4% more ownership
Funds ownership: 156.61% [Q4 2024] → 180.01% (+23.4%) [Q1 2025]
6% less capital invested
Capital invested by funds: $9.84B [Q4 2024] → $9.21B (-$633M) [Q1 2025]
7% less funds holding in top 10
Funds holding in top 10: 15 [Q4 2024] → 14 (-1) [Q1 2025]
8% less funds holding
Funds holding: 727 [Q4 2024] → 669 (-58) [Q1 2025]
34% less repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 267
39% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 119
50% less call options, than puts
Call options by funds: $1.08B | Put options by funds: $2.17B
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Based on 8 articles about XBI published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Neutral
The Street
2 days ago
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Negative
Investors Business Daily
3 days ago
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
Positive
CNBC Television
4 days ago
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Neutral
Seeking Alpha
5 days ago
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar objective, and are over-diversified. For reasons I explain here.
Neutral
CNBC Television
2 weeks ago
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Negative
Market Watch
3 weeks ago
Home builders lose confidence, resort to price cuts as buyers steer clear of housing market
Builders' confidence in the housing market sank in June, the National Association of Home Builders said.
Neutral
Zacks Investment Research
4 weeks ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
Neutral
Seeking Alpha
1 month ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Negative
Market Watch
1 month ago
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Charts implemented using Lightweight Charts™